<?xml version="1.0" encoding="UTF-8"?>
<p id="par0225">Among these cytokines, several have been suggested as a potential therapeutic target. IL-1, for example, is activated after the binding between COVID-19 and toll-like receptors (TLR). Released IL-1 mediates lung inflammation, fever and fibrosis. IL-1 is also known for its important role in the progression of pulmonary fibrosis [
 <xref rid="bib0245" ref-type="bibr">49</xref>]. IL-6 is also an important cytokine during respiratory viral infections, and it has been reported that, during this COVID-19 pandemic, it has been correlated with pulmonary infection severity in ICU patients [
 <xref rid="bib0245" ref-type="bibr">49</xref>,
 <xref rid="bib0375" ref-type="bibr">75</xref>]. Both IL-1 and IL-6 have been presented as potential therapeutic targets [
 <xref rid="bib0370" ref-type="bibr">74</xref>,
 <xref rid="bib0375" ref-type="bibr">75</xref>].
</p>
